Abstract
OBJECTIVE: This study aimed to evaluate the efficacy of Sihuang Zijin powder colloid in the treatment of infusion phlebitis in patients with tumors. METHODS: In this randomized controlled trial, 110 patients with grade II-III phlebitis were randomly allocated to either of two groups: the experimental group and the control group. Patients in the experimental group received Sihuang Zijin powder colloid, and those in the control group were treated with a hydrocolloid. The severity of phlebitis was assessed using the Infusion Nurses Society grading criteria for phlebitis and the level of pain was assessed using a visual analog scale after 24 hours. Additional outcome measures included the duration required for pain relief, the time taken for resolution of the extent of redness and swelling, and patient satisfaction levels. RESULTS: Following 24 hours of treatment, there were notable differences between the two groups in the severity of phlebitis and pain scores. Patients in the experimental group exhibited a significantly shorter time to pain relief and resolution of swelling compared to those in the control group. Additionally, patient satisfaction was significantly higher in the experimental group. CONCLUSION: Sihuang Zijin powder colloid was effective in the treatment of infusion phlebitis in patients with tumors, with treated patients demonstrating superior outcomes in terms of pain relief, resolution of swelling, and patient satisfaction.